

... .. C
... ..
... ..

温州康宁医院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.

Company incorporated in the People's Republic of China

3. $\int_0^1 \int_0^1 \int_0^1 \frac{1}{1+x+y+z} dx dy dz = A \ln 2 + B \ln 3 + C \ln 4$

3. *Explain the difference between the two types of cells. A* *prokaryotic cell* is a cell that lacks a nucleus and other membrane-bound organelles. *E. coli* is a prokaryotic cell. *C* *eukaryotic cell* is a cell that has a nucleus and other membrane-bound organelles. *C* *animal cell* is a eukaryotic cell that lacks a cell wall and chloroplasts. *C* *plant cell* is a eukaryotic cell that has a cell wall and chloroplasts.

- [illegible]

Figure 1. The effect of the α -value on the AICc and AICc-adj. AICc and AICc-adj. were calculated for the 1000 simulated data sets for each of the 1000 values of α (0.001 to 1.000) and for each of the 1000 values of β (0.001 to 1.000). The mean AICc and AICc-adj. values were calculated for each value of α and β . The AICc and AICc-adj. values were plotted against α and β values. The AICc and AICc-adj. values were plotted against α and β values. The AICc and AICc-adj. values were plotted against α and β values.


1. $\lim_{n \rightarrow \infty} \frac{1}{n} \sum_{k=1}^n \frac{1}{k} = \ln 2$. A classic result in analysis, often proved using the integral test or the harmonic series.

B  **A**

28, 2022 B15,816,447.

A  **C**

...and the other is the fact that the system is not yet fully developed.

- (i)  A single neuron with input A , output B , and feedback C .

- (A) A
- C
- A
- C

- (iii) $\mathcal{A} \subseteq \mathcal{B}$ and $\mathcal{B} \subseteq \mathcal{A}$ are not true. $\mathcal{A} \subseteq \mathcal{B}$ is true because $\mathcal{A}$ is a subset of $\mathcal{B}$. $\mathcal{B} \subseteq \mathcal{A}$ is false because $\mathcal{B}$ is not a subset of $\mathcal{A}$.

Major Limitations on the Review Scope of the Supplementary Report of the Independent Investigation

- (1) The review scope of the Supplementary Report of the Independent Investigation is limited to the scope of the investigation. The review scope of the Supplementary Report of the Independent Investigation is limited to the scope of the investigation. The review scope of the Supplementary Report of the Independent Investigation is limited to the scope of the investigation.
- (2) The review scope of the Supplementary Report of the Independent Investigation is limited to the scope of the investigation. The review scope of the Supplementary Report of the Independent Investigation is limited to the scope of the investigation. The review scope of the Supplementary Report of the Independent Investigation is limited to the scope of the investigation.

Opinions of the Independent Investigation Committee and the Board on the Supplementary Report of the Independent Investigation

The Independent Investigation Committee and the Board have reviewed the Supplementary Report of the Independent Investigation. The Independent Investigation Committee and the Board have reviewed the Supplementary Report of the Independent Investigation. The Independent Investigation Committee and the Board have reviewed the Supplementary Report of the Independent Investigation.

25.16. -1.16. 8.1.16.3

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Conflict of Interest Reporting Mechanism As part of the internal control review, the audit team identified a weakness in the conflict of interest reporting mechanism. The current process requires employees to declare conflicts of interest annually, but it does not include a mechanism for reporting conflicts of interest that arise between annual declarations. This could result in conflicts of interest going unreported and potentially leading to conflicts of interest that could impact the integrity of the financial reporting process. The audit team recommended that the company implement a mechanism for reporting conflicts of interest that arise between annual declarations. This could be achieved by implementing a conflict of interest reporting form that employees can complete and submit to the appropriate authority at any time during the year. The form should include a section for reporting conflicts of interest that arise between annual declarations, and the appropriate authority should be responsible for reviewing and addressing any reported conflicts of interest.	The company has implemented a conflict of interest reporting mechanism that requires employees to declare conflicts of interest annually. The company has also implemented a mechanism for reporting conflicts of interest that arise between annual declarations. This mechanism includes a conflict of interest reporting form that employees can complete and submit to the appropriate authority at any time during the year. The appropriate authority is responsible for reviewing and addressing any reported conflicts of interest.

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Succession Plan The Board of Directors has approved a succession plan for the CEO and the Chairman of the Board. The plan includes a process for identifying and developing potential successors, as well as a process for transitioning the company to a new leader. The plan also includes a process for ensuring the continuity of the company's operations in the event of a sudden change in leadership.	
Risk Assessments – Anti-Money Laundering Mechanism The company has implemented a robust anti-money laundering (AML) mechanism. This mechanism includes a risk assessment process that identifies and evaluates the company's exposure to AML risks. The company also has a process for monitoring and reporting suspicious transactions, as well as a process for conducting due diligence on new and existing customers.	Anti-Money Laundering (AML) Mechanism

Key Internal Control Issues	Rectifications
Activity-level review	
Revenue and Accounts Receivable Management – Bad Debt Provision As at 31 March 2019, the Accounts Receivable balance was \$1,200,000. The Bad Debt Provision was \$72,000. The provision was calculated as follows: A. The provision was calculated as follows: B. The provision was calculated as follows: C. The provision was calculated as follows:	A. The provision was calculated as follows: G. The provision was calculated as follows: A. The provision was calculated as follows: 60% 100% (The provision was calculated as follows: C. The provision was calculated as follows:)
Bank and Cash Management – Charitable Donation Management The Charitable Donation Management was as follows: A. The Charitable Donation Management was as follows: B. The Charitable Donation Management was as follows: C. The Charitable Donation Management was as follows: D. The Charitable Donation Management was as follows: E. The Charitable Donation Management was as follows: F. The Charitable Donation Management was as follows: G. The Charitable Donation Management was as follows: H. The Charitable Donation Management was as follows: I. The Charitable Donation Management was as follows: J. The Charitable Donation Management was as follows: K. The Charitable Donation Management was as follows: L. The Charitable Donation Management was as follows: M. The Charitable Donation Management was as follows: N. The Charitable Donation Management was as follows: O. The Charitable Donation Management was as follows: P. The Charitable Donation Management was as follows: Q. The Charitable Donation Management was as follows: R. The Charitable Donation Management was as follows: S. The Charitable Donation Management was as follows: T. The Charitable Donation Management was as follows: U. The Charitable Donation Management was as follows: V. The Charitable Donation Management was as follows: W. The Charitable Donation Management was as follows: X. The Charitable Donation Management was as follows: Y. The Charitable Donation Management was as follows: Z. The Charitable Donation Management was as follows:	A. The Charitable Donation Management was as follows: A. The Charitable Donation Management was as follows: B. The Charitable Donation Management was as follows: C. The Charitable Donation Management was as follows: D. The Charitable Donation Management was as follows: E. The Charitable Donation Management was as follows: F. The Charitable Donation Management was as follows: G. The Charitable Donation Management was as follows: H. The Charitable Donation Management was as follows: I. The Charitable Donation Management was as follows: J. The Charitable Donation Management was as follows: K. The Charitable Donation Management was as follows: L. The Charitable Donation Management was as follows: M. The Charitable Donation Management was as follows: N. The Charitable Donation Management was as follows: O. The Charitable Donation Management was as follows: P. The Charitable Donation Management was as follows: Q. The Charitable Donation Management was as follows: R. The Charitable Donation Management was as follows: S. The Charitable Donation Management was as follows: T. The Charitable Donation Management was as follows: U. The Charitable Donation Management was as follows: V. The Charitable Donation Management was as follows: W. The Charitable Donation Management was as follows: X. The Charitable Donation Management was as follows: Y. The Charitable Donation Management was as follows: Z. The Charitable Donation Management was as follows:

B. 2022年12月31日, 本公司在A股、C股两个市场均无成交, 且未发生任何交易。C股在2022年12月31日收盘价为A股收盘价的100%。A股在2022年12月31日收盘价为B股收盘价的100%。C股在2022年12月31日收盘价为A股收盘价的100%。

CONTINUED SUSPENSION OF TRADING

A. 2022年12月31日, 本公司在A股、C股两个市场均无成交, 且未发生任何交易。C股在2022年12月31日收盘价为A股收盘价的100%。A股在2022年12月31日收盘价为B股收盘价的100%。C股在2022年12月31日收盘价为A股收盘价的100%。

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

B. 2022年12月31日, 本公司在A股、C股两个市场均无成交, 且未发生任何交易。C股在2022年12月31日收盘价为A股收盘价的100%。A股在2022年12月31日收盘价为B股收盘价的100%。C股在2022年12月31日收盘价为A股收盘价的100%。

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
C. 2022年12月31日

2022年12月31日, 本公司在A股、C股两个市场均无成交, 且未发生任何交易。C股在2022年12月31日收盘价为A股收盘价的100%。A股在2022年12月31日收盘价为B股收盘价的100%。C股在2022年12月31日收盘价为A股收盘价的100%。

A. 2022年12月31日, 本公司在A股、C股两个市场均无成交, 且未发生任何交易。C股在2022年12月31日收盘价为A股收盘价的100%。A股在2022年12月31日收盘价为B股收盘价的100%。C股在2022年12月31日收盘价为A股收盘价的100%。